肺静脉隔离与假干预治疗症状性心房颤动的比较:SHAM-PVI随机临床试验
在2个英国三级中心开展的双盲随机临床试验,纳入126例症状性阵发性或持续性心房颤动患者,比较冷冻消融肺静脉隔离(n=64)与膈神经起搏假手术(n=62)的疗效。主要终点为排除3个月空白期后6个月的心房颤动负荷。结果显示消融组6个月房颤负荷较基线绝对平均变化为60.31%,假手术组为35.0%,几何均数差异0.25(95%CI 0.15-0.42,P<.001),消融组在症状及生活质量方面也有显著改善。
要点
- 肺静脉隔离冷冻消融组6个月房颤负荷较基线绝对平均变化60.31%,假手术组为35.0%。
- 6个月房颤负荷几何均数差异0.25(95%CI 0.15-0.42,P<.001),差异有统计学意义。
- 6个月心房颤动对生活质量影响量表总分估计差异18.39分(95%CI 11.48-25.30),倾向导管消融。
核心结论
- 与假手术相比,肺静脉隔离在6个月时使心房颤动负荷出现有统计学意义且有临床意义的降低,同时症状和生活质量有实质性改善。
研究设计与样本
- 双盲随机临床试验,于2020年1月至2024年3月在英国2个三级中心开展。
- 纳入症状性阵发性或持续性心房颤动患者,共126例随机分组(平均年龄66.8岁;男性89例[70.63%];阵发性心房颤动20.63%)。
- 主要排除标准包括长程持续性心房颤动、既往左心房消融、需消融治疗的其他心律失常、左心房5.5 cm或更大、射血分数低于35%。
- 参与者随机接受冷冻消融肺静脉隔离(n=64)或膈神经起搏假手术(n=62)。
主要发现
- 主要终点为排除3个月空白期后6个月的心房颤动负荷,通过植入式循环记录仪测量。
- 6个月时房颤负荷较基线的绝对平均变化:消融组60.31% vs 假手术组35.0%,几何均数差异0.25(95%CI 0.15-0.42,P<.001)。
- 6个月时心房颤动对生活质量影响量表总分的估计差异为18.39分(95%CI 11.48-25.30分),倾向导管消融。
- 6个月时简表36总体健康评分的估计差异为9.27分(95%CI 3.78-14.76分),消融组改善幅度更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are concerns that pulmonary vein isolation for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical trials have been conducted. OBJECTIVE: To determine whether pulmonary vein isolation is more effective than a sham procedure for improving outcomes in atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS: Double-blind randomized clinical trial conducted at 2 tertiary centers in the UK between January 2020 and March 2024 among patients with symptomatic paroxysmal or persistent atrial fibrillation. Major exclusion criteria included long-standing persistent atrial fibrillation, prior left atrium ablation, other arrhythmias requiring ablative therapy, a left atrium of 5.5 cm or larger, and ejection fraction of less than 35%. INTERVENTION: Participants were randomly assigned to receive pulmonary vein isolation with cryoablation (n = 64) or a sham procedure with phrenic nerve pacing (n = 62). MAIN OUTCOMES AND MEASURES: The primary end point was atrial fibrillation burden at 6 months, excluding a 3-month blanking period. Secondary outcomes included quality-of-life measures, time to events, and safety. Atrial fibrillation burden was measured by an implantable loop recorder. RESULTS: A total of 126 participants were randomized (mean age, 66.8 years; 89 men [70.63%]; 20.63% with paroxysmal atrial fibrillation). The absolute mean atrial fibrillation burden change from baseline to 6 months was 60.31% in the ablation group and 35.0% in the sham group (geometric mean difference, 0.25; 95% CI, 0.15-0.42; P < .001). The estimated difference in the overall Atrial Fibrillation Effect on Quality of Life score at 6 months, favoring catheter ablation, was 18.39 points (95% CI, 11.48-25.30 points). The Short Form 36 general health score also improved substantially more with ablation, with an estimated difference of 9.27 points at 6 months (95% CI, 3.78-14.76 points). CONCLUSIONS AND RELEVANCE: Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04272762.
引用
- Dulai R, Sulke N, Freemantle N, et al. Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial. JAMA. 2024. PMID: 39221629. doi:10.1001/jama.2024.17921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。